Rapt Therapeutics started at Buy at Clear Street on RPT904b opportunity
Clear Street initiated coverage of Rapt Therapeutics (RAPT) with a Buy rating and $3 price target. The firm's bullish call is driven by a strong conviction in RPT904b – a potentially best-in-class anti-IgE antibody for food allergy and chronic spontaneous urticaria that is comparable to Roche (RHHBY) and Novartis' (NVS) Xolair, the analyst tells investors in a research note. Rapt's 76% stock decline over 12 months relative to XBI's 12% is primarily attributable to an unrelated asset discontinuation and has created a 'significant opportunity', the firm added.
Confident Investing Starts Here:
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
How to Organize a Health Technology Business with Focus on 10+ Organizational Archetypes
Discover the evolving organizational structures of digital health businesses in the Pharma and MedTech sectors. This report analyzes 11 HealthTech archetypes over 15 years, offering insights on performance across key KPIs, future trends, and strategic recommendations. Featured companies include Bayer, Roche, and more. Dublin, June 09, 2025 (GLOBE NEWSWIRE) -- The "How to Organize a HealthTech Business?" report has been added to offering. This report sheds light on how to organize digital health businesses, especially at large Pharma and MedTech companies. By looking at how other companies have been managing their HealthTech businesses over the last 15 years, 11 different HealthTech organizational archetypes are being detailed out in the report, including their objectives, responsibilities, team sizes, target partner company stages, governance, value propositions for their partners, business impact evaluations across 4 KPIs and real-life examples from companies who had deployed these structures. Performance of the 11 archetypes are then evaluated and compared across the four main KPIs which are based on finding partners, launching solutions, driving usages & cultural change support. Based on the evaluation of the success and impact of these archetypes, the report presents a benchmarking table of HealthTech business organizations today. With a deep-dive into the evolving trends in HealthTech business organizations responding to the changing market conditions across three main market phases, 5 trend points for future and relevant recommendations are provided on what needs to be done to stay competitive and move forward in growing digital health market. Questions the report answers: What are the archetypes to organize HealthTech businesses at Pharma and MedTech companies? What are the different objectives and responsibilities of each organizational archetype? How are the archetypes governed at larger corporates? How does each organizational archetype perform? Which Pharma and MedTech apply which archetype to manage their HealthTech business today? How did the archetypes evolve to adept the market conditions today? What does the market require for organization of HealthTech businesses in 3-5 years? Interested parties can benefit from this report in the following ways: Consultants: gain insights into different organizational structures within the HealthTech industry, and enhance the ability to advise clients on optimal structuring and strategic alignment for digital health initiatives Strategy heads: understand how leading organizations structure their HealthTech initiatives, which can inform strategic planning and decision-making processes Business unit heads: understand how to integrate digital health solutions into the units effectively, determine the most suitable structure for the unit, and align with overall corporate objectives Digital health unit heads: benchmark your organizational structure against others, know what is needed in terms organizational structure to stay competitive in the growing digital health market, and optimize your organizational structure to foster innovation and integration with business units In this report, the following companies are mentioned: Bayer Roche Biogen Sanofi Siemens Healtineers GE Healthcare Janssen (J&J) MSD Merck KGaA Novartis Becton Dickenson and Company *30 min report consultation with a research analyst available with the purchase of an enterprise license Key Topics Covered: Archetype-1: Central Teams Archetype-2: De-Central Teams Archetype-3: Carve-Outs Archetype-4: Innovation Hubs Archetype-5: Incubators Archetype-6: Accelerators Archetype-7: Collaborative Accelerators Archetype-8: People Accelerators Archetype-9: Marketplace Organizations Archetype-10: Venture Funds Archetype-11: Outsourcing The Influence of Market Maturity on the Development of HealthTech Organizational Forms Building Successful HealthTech Teams for the Next 3-5 Years For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
4 days ago
- Business Insider
RAPT Therapeutics (RAPT) Has a New Rating from Clear Street
RAPT Therapeutics (RAPT – Research Report) received a Buy rating and a $3.00 price target from Clear Street analyst Kaveri Pohlman yesterday. The company's shares closed yesterday at $1.02. Confident Investing Starts Here: Pohlman covers the Healthcare sector, focusing on stocks such as Protagonist Therapeutics, Akero Therapeutics, and RAPT Therapeutics. According to TipRanks, Pohlman has an average return of -12.3% and a 27.06% success rate on recommended stocks. RAPT Therapeutics has an analyst consensus of Hold, with a price target consensus of $3.75, which is a 267.65% upside from current levels. In a report released on May 22, H.C. Wainwright also reiterated a Buy rating on the stock with a $6.00 price target.
Business Insider
4 days ago
- Business Insider
Rapt Therapeutics started at Buy at Clear Street on RPT904b opportunity
Clear Street initiated coverage of Rapt Therapeutics (RAPT) with a Buy rating and $3 price target. The firm's bullish call is driven by a strong conviction in RPT904b – a potentially best-in-class anti-IgE antibody for food allergy and chronic spontaneous urticaria that is comparable to Roche (RHHBY) and Novartis' (NVS) Xolair, the analyst tells investors in a research note. Rapt's 76% stock decline over 12 months relative to XBI's 12% is primarily attributable to an unrelated asset discontinuation and has created a 'significant opportunity', the firm added. Confident Investing Starts Here:
